Literature DB >> 975718

Protein binding of salicylate in uremic and normal plasma.

O Borgå, I O Cederlöf, V A Ringberger, A Norlin.   

Abstract

Protein binding of salicylate was studied by equilibrium dialysis at 37 degrees C in plasma from uremic patients and healthy subjects. The protein binding was considerably lower in the uremic plasma at all salicylate concentrations studied (14 to 1,400 mug/ml). Scatchard plots of the data were computer-analyzed assuming binding to the classes of binding sites. According to this analysis, the binding to the class of primary binding sites was considerably decreased in the uremic plasma. In addition to the effect of the uremic state, the binding was considerably decreased at high therapeutic plasma levels and at low albumin levels. The combined effect of two or three of these factors may lead to unexpectedly high unbound fractions of salicylate, which should be considered in the monitoring of plasma salicylate levels in patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 975718     DOI: 10.1002/cpt1976204464

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.

Authors:  A Viani; G Rizzo; M Carrai; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 3.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 4.  Pharmacokinetic evaluation of hemodialysis in acute drug overdose.

Authors:  S Takki; J G Gambertoglio; D H Honda; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

5.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Protein binding of enprofylline.

Authors:  K Tegnér; O Borgå; I Svensson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.

Authors:  J Shen; S Wanwimolruk; R D Purves; E G McQueen; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 8.  A reassessment of the treatment of salicylate poisoning.

Authors:  L Notarianni
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 9.  Aspirin and related derivatives of salicylic acid.

Authors:  S P Clissold
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Monitoring plasma concentrations of salicylate.

Authors:  M Mandelli; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.